Progyny to Discuss Updated Financial Expectations at Upcoming JP Morgan Healthcare Conference
| PGNY Stock | USD 23.54 0.29 1.25% |
Slightly above 55% of Progyny's investors are presently thinking to get in. The analysis of overall sentiment of trading Progyny stock suggests that some investors are interested at this time. Progyny's investing sentiment can be driven by a variety of factors including economic data, Progyny's earnings reports, geopolitical events, and overall market trends.
Progyny |
Anticipates Fourth Quarter and Full Year Results to be Slightly Above Previously Provided Financial Guidance NEW YORK, Jan. 13, 2025 -- Pro
Read at gurufocus.com
 |
Progyny Fundamental Analysis
We analyze Progyny's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Progyny using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Progyny based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Current Ratio
Current Ratio Comparative Analysis
Progyny is currently under evaluation in current ratio category among its peers. Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.
Progyny Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Progyny stock to make a market-neutral strategy. Peer analysis of Progyny could also be used in its relative valuation, which is a method of valuing Progyny by comparing valuation metrics with similar companies.
Peers
Progyny Related Equities
| NRC | National Research | 2.39 | ||||
| GDRX | Goodrx Holdings | 2.27 | ||||
| VEEV | Veeva Systems | 2.05 | ||||
| EVH | Evolent Health | 1.63 | ||||
| TXG | 10X Genomics | 1.62 | ||||
| SLP | Simulations Plus | 1.39 | ||||
| HSTM | HealthStream | 1.36 | ||||
| PHR | Phreesia | 1.01 | ||||
| CERT | Certara | 0.14 | ||||
| PRVA | Privia Health | 0.13 | ||||
| TDOC | Teladoc | 0.1 | ||||
| DH | Definitive Healthcare | 0.20 | ||||
| HCAT | Health Catalyst | 1.95 |
Additional Tools for Progyny Stock Analysis
When running Progyny's price analysis, check to measure Progyny's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Progyny is operating at the current time. Most of Progyny's value examination focuses on studying past and present price action to predict the probability of Progyny's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Progyny's price. Additionally, you may evaluate how the addition of Progyny to your portfolios can decrease your overall portfolio volatility.